Here are 2 of the figures from the REGN/SNY briefing document showing a dose-response for alirocumab. images.investorshub.advfn.com/images/uploads/2015/6/6/kvncaAlirocumab_Fig_6_efficacy_REGN_Briefing_Doc.PNG images.investorshub.advfn.com/images/uploads/2015/6/6/wnjykAlirocumab_Fig_7_efficacy_REGN_Briefing_Doc.PNG